Oncology Tube ✓

@oncologytube · Temecula, CA · joined 30 Sep 2009

Stay Up To Date with our Newsletter: https://t.co/BQxZ2gkon8 Delivering top-quality multimedia to oncologists, hematologists, and cancer pros!

17 098Followers

799Following

141 683Posts total

3KViews on collected posts

Son gönderiler

Oncology Tube ✓@oncologytube11 Sep

MATTERHORN final OS — 22% reduction in risk of death; 3-y OS 69% vs 62%. Full data: https://t.co/q3tbnDroSk 586 views · 4 likes · 1 reposts · 3 replies Open on X →

Oncology Tube ✓@oncologytube11 Sep

WATCH: MATTERHORN final OS — Imfinzi + FLOT in resectable gastric/GEJ 🩺 👉 https://t.co/q3tbnDroSk 🔹 Perioperative durvalumab + FLOT vs placebo + FLOT (Lancet) 🔹 22% reduction in risk of death; median FU 43 mo; median OS NR both arms 🔹 3-year OS 69% vs 62% — EFS already https://t.

621 views · 8 likes · 1 reposts · 4 replies Open on X →

Oncology Tube ✓@oncologytube10 Sep

WATCH: Etentamig CERVINO — ORR 74% in triple-class RRMM 🩸 👉 https://t.co/v7JMayFQD5 🔹 Investigational BCMA×CD3 BiTE (ABBV-383) vs SAT (N=393) 🔹 ORR 74.0% vs 45.7%; PFS HR 0.40 (both P<0.0001) 🔹 Single step-up then Q4W; CRS 28% mostly low-grade — not FDA-approved; full data https:

687 views · 5 likes · 2 reposts · 5 replies Open on X →

Oncology Tube ✓@oncologytube10 Sep

ARROS-1’s zidesamtinib showed a 44% ORR, with DOR ≥6 months in 82% of responders. Full data: https://t.co/QCOd9YSZMi 419 views · 0 likes · 1 reposts · 0 replies Open on X →

Oncology Tube ✓@oncologytube10 Sep

WATCH: Jideytro FDA — ROS1+ NSCLC after prior TKI (ARROS-1) 🫁 👉 https://t.co/QCOd9YSZMi 🔹 Zidesamtinib approved after ≥1 prior ROS1 TKI 🔹 ARROS-1 n=117: ORR 44%; DOR ≥6 mo in 82% of responders 🔹 100 mg PO daily — not interchangeable with taletrectinib Full data on https://t.co/yg

646 views · 4 likes · 2 reposts · 6 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 5 gönderi, 10K–100K takipçi aralığıyla yan yana. takipçi aralığının tam medyanında.

Medyan görüntülenme621bu hesap92410K–100K için medyan

Erişim, %3.63%bu hesap3.62%10K–100K için medyan

Etkileşim, %1.75%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	621	924	0.67×
Erişim (görüntülenme ÷ takipçi)	3.63%	3.62%	1.00×
Etkileşim oranı	1.75%	1.52%	1.15×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

64610 Sep

419

687

62111 Sep

586

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.86%10 Sep

0.24%

1.75%

2.09%11 Sep

1.37%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes45.7%21 in total

Reposts15.2%7 in total

Replies39.1%18 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar